BridgeBio Oncology Therapeutics, Inc.
BBOT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BBOT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BBOT
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for cancer, with lead candidates BBO-8520, BBO-10203, and BBO-11818 in clinical trials.
Key risk: No revenue or approved products
BioSniper Score
Based on 5 of 6 signals
Market Cap
$700.7M
Cash Runway
15.0 moLead Asset
bbo-11818 (Phase 1)Next Catalyst
Phase3_Topline · Dec 28, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 11 clinical trials · 1 catalyst for BridgeBio Oncology Therapeutics, Inc..
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for cancer, with lead candidates BBO-8520, BBO-10203, and BBO-11818 in clinical trials.
- BBOT has no approved products and has never generated revenue, with all resources devoted to R&D since becoming an independent entity in May 2024 [sec_mda · as of 2026-03-05].
- Lead product candidates include BBO-8520, BBO-10203, and BBO-11818, currently in clinical trials such as ONKORAS-101, BREAKER-101, and KONQUER-101 [sec · filed 2025-08-13].
- Cash and equivalents were $54.2M as of 2026-06-30, with a net loss of -$56.5M for the period and negative shareholders' equity of -$227.7M [sec].
- BBOT estimates its existing cash will fund operations into early 2028, but additional capital will be needed to advance its pipeline [sec_mda · as of 2026-03-05].
- The company faces significant risks including clinical trial enrollment delays, manufacturing challenges, and reliance on future financing [sec_mda · as of 2026-03-05].
What works
- BBOT has a focused pipeline of three clinical-stage candidates targeting oncology, with ongoing trials (ONKORAS-101, BREAKER-101, KONQUER-101) that could address unmet medical needs [sec · filed 2025-08-13].
- The company has sufficient cash runway into early 2028, providing a multi-year horizon to advance its programs without immediate financing pressure [sec_mda · as of 2026-03-05].
What to weigh
- BBOT has no approved products, no revenue, and a history of significant operating losses, with a net loss of -$56.5M in the latest quarter and negative equity of -$227.7M [sec].
- Drug development is highly uncertain; BBOT has never completed a clinical trial and may face delays in patient enrollment, manufacturing, or regulatory approval [sec_mda · as of 2026-03-05].
- The company will require substantial additional capital to continue R&D, and failure to raise funds could force program delays or elimination [sec_mda · as of 2026-03-05].
From the filings
Quoted directly from source documents.
BBOT's cash runway extends into early 2028.
“BBOT estimates that its existing cash, cash equivalents and short-term marketable securities as of the date of this report will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into early 2028.”
SEC MD&A · March 5, 2026
BBOT's pipeline includes BBO-8520, BBO-10203, and BBO-11818 in clinical trials.
“the progress and results of the ONKORAS-101, BREAKER-101 and KONQUER-101 clinical trials; the clinical and therapeutic potential of BBO-8520, BBO-102”
SEC filings · August 13, 2025
Catalyst timeline
- 2026-12-28 · Phase3_Topline — Phase 3 Topline: Early Commencement of Adjuvant Chemotherapy for Stage III Colon Cancer: a Multicenter Randomized Tri — Topline data from a Phase 3 trial evaluating early commencement of adjuvant chemotherapy in Stage III colon cancer; results may inform BBOT's pipeline strategy.
Risks & what to watch (4)›
Key risks
- No revenue or approved products — BBOT has never generated revenue and has no approved products, relying entirely on future clinical and regulatory success [sec_mda · as of 2026-03-05].
- Clinical trial enrollment delays — Inability to enroll sufficient patients could cause significant delays or trial abandonment, increasing costs and jeopardizing approval [sec_mda · as of 2026-03-05].
- Need for additional capital — BBOT will require substantial funding to continue R&D; failure to raise capital may force program reductions or elimination [sec_mda · as of 2026-03-05].
- Manufacturing and supply risks — Timely manufacture of sufficient quantities for clinical trials is a key risk, with potential delays from public health or geopolitical events [sec_mda · as of 2026-03-05].
What to watch
- Progress and data readouts from the ONKORAS-101, BREAKER-101, and KONQUER-101 clinical trials for BBO-8520, BBO-10203, and BBO-11818 [sec · filed 2025-08-13].
- BBOT's ability to secure additional financing to extend its cash runway beyond early 2028 [sec_mda · as of 2026-03-05].
- Regulatory milestones, including any FDA or EMA interactions regarding the lead candidates [sec_mda · as of 2026-03-05].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BridgeBio Oncology Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BridgeBio Oncology Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
15.0 months
D/E 0.17 · 0% dilution
Lead: Phase 1
2 candidates
1 upcoming, next in ~120d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
64
Total value held
$305.2M
| Holder | Shares | Value |
|---|---|---|
| deerfield management company, l.p. | 4,885,446 | $43.7M |
| omega fund management, llc | 3,289,661 | $29.4M |
| wellington management group llp | 2,818,348 | $25.2M |
| enavate sciences gp, llc | 2,626,946 | $23.5M |
| citadel advisors llc | 2,528,762 | $22.6M |
| novo holdings a/s | 2,185,923 | $19.6M |
| blackrock, inc. | 2,088,297 | $18.7M |
| laurion capital management lp | 1,922,656 | $17.2M |
| armistice capital, llc | 1,328,000 | $11.9M |
| vanguard capital management llc | 1,076,882 | $9.6M |
Showing top 10 of 64 institutional holders of BridgeBio Oncology Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 11.7%
- Days to cover
- 7.0
- Shares short
- 3,320,560
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BBOT short interestGovernance
Frequently asked questions
What is the AI investment thesis for BridgeBio Oncology Therapeutics, Inc.?
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for cancer, with lead candidates BBO-8520, BBO-10203, and BBO-11818 in clinical trials.
What is BridgeBio Oncology Therapeutics, Inc.'s lead drug candidate?
BridgeBio Oncology Therapeutics, Inc.'s most advanced tracked candidate is bbo-11818 (Phase 1) for Non-Small Cell Lung Cancer.
What is BridgeBio Oncology Therapeutics, Inc.'s next catalyst?
BridgeBio Oncology Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Early Commencement of Adjuvant Chemotherapy for Stage III Colon Cancer: a Multicenter Randomized Tri" — expected December 28, 2026.
Who is the CEO of BridgeBio Oncology Therapeutics, Inc.?
Dr. Pedro J. Beltran M.D., Ph.D. is the chief executive officer of BridgeBio Oncology Therapeutics, Inc. (BBOT).
Where is BridgeBio Oncology Therapeutics, Inc. headquartered?
BridgeBio Oncology Therapeutics, Inc. (BBOT) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.